IPSWICH, Mass., June 10, 2021 /PRNewswire/ — New England Biolabs (NEB®), a number one provider of reagents for the life sciences, right now introduced the launch of a web-based device for monitoring the emergence of SARS-CoV-2 variants and their potential influence on COVID-19 diagnostic assessments. The Primer Monitor Device, which is up to date repeatedly, offers easy visualization of recognized variants recognized within the SARS-CoV-2 genome and provides perception into the place generally used or user-defined primer set evaluation could also be worthwhile.
Because the SARS-CoV-2 virus has continued to unfold and mutate, issues have been raised concerning the effectiveness of present diagnostic assessments to detect new strains of the virus. The U.S. Meals and Drug Administration (FDA) issued steerage advising COVID-19 diagnostic builders to guage the influence of rising and future SARS-CoV-2 variants on present diagnostic assessments by routinely monitoring sequence alignment of primer/probe sequences with open entry SARS-CoV-2 genomes databases comparable to GISAID, a world science initiative and first supply that gives open-access to genomic knowledge of influenza viruses and the novel coronairus accountable for COVID-19.
“With the issuance of the FDA steerage, we noticed a necessity for creating a web-based device for diagnostic researchers and builders that visualizes the entire SARS-CoV-2 genomic knowledge and variant strains uploaded to the GISAID database,” stated Steven Chiu, Product Advertising Supervisor, DNA Amplification, at NEB. “The device is pre-loaded with generally used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (presently v3). Customers can monitor these predefined primer units in addition to add their very own sequences of curiosity, with the choice to subscribe and be alerted ought to variation cross a specified threshold in a geographic area of curiosity.”
Extra data may be discovered on this technical notice, which can also be out there on neb.com. To entry the device, please go to https://primer-monitor.neb.com/
About New England Biolabs
Established within the mid 1970’s, New England Biolabs, Inc. (NEB) is the trade chief within the discovery and manufacturing of enzymes for molecular biology functions and now provides the most important choice of recombinant and native enzymes for genomic analysis. NEB continues to increase its product choices into areas associated to PCR, gene expression, pattern preparation for subsequent technology sequencing, artificial biology, glycobiology, epigenetics and RNA evaluation. Moreover, NEB is targeted on strengthening alliances that allow new applied sciences to succeed in key market sectors, together with molecular diagnostics growth. New England Biolabs is a privately held firm, headquartered in Ipswich, MA, and has intensive worldwide distribution via a community of unique distributors, brokers and eight subsidiaries situated in Australia, Canada, China, France, Germany, Japan, Singapore and the UK. For extra details about New England Biolabs go to www.neb.com.
NEB® and NEW ENGLAND BIOLABS® are registered logos of New England Biolabs, Inc.
View unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/new-england-biolabs-inc-launches-primer-monitor-tool-for-tracking-sars-cov-2-variants-that-may-impact-primers-used-in-diagnostic-assays-301310243.html
SOURCE New England Biolabs
[ Back To TMCnet.com’s Homepage ]